Proteostasis Network Dysfunction Comparison Across Neurodegenerative Diseases

Migration, Crosslink

📖

Proteostasis Network Dysfunction Comparison Across Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-proteostasis-network-com

📖 Wiki Page

mechanism3519 wordssynced 2026-04-02

Proteostasis Network Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of protein quality control mechanisms, impairments, and therapeutic approaches

Overview

The proteostasis network is the cell's quality control system for proteins, consisting of molecular chaperones, the ubiquitin-proteasome system (UPS), and autophagy-lysosomal pathways. Proteostasis failure is a common pathological feature across all major neurodegenerative diseases, leading to accumulation of toxic protein aggregates [[PMID: 18276879]]. This page compares proteostasis impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD) [[PMID: 20437213]].

Comparison Matrix

...

Proteostasis Network Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of protein quality control mechanisms, impairments, and therapeutic approaches

Overview

The proteostasis network is the cell's quality control system for proteins, consisting of molecular chaperones, the ubiquitin-proteasome system (UPS), and autophagy-lysosomal pathways. Proteostasis failure is a common pathological feature across all major neurodegenerative diseases, leading to accumulation of toxic protein aggregates [[PMID: 18276879]]. This page compares proteostasis impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD) [[PMID: 20437213]].

Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Proteostasis Defect | ↓ Chaperone activity, impaired UPS, autophagy failure [[PMID: 25234020]] | ↓ Chaperone activity, α-synuclein overload [[PMID: 31073215]] | SOD1/TDP-43 aggregates overwhelm proteostasis [[PMID: 31467462]] | GRN deficiency, TDP-43 pathology [[PMID: 33001069]] | Mutant huntingtin impairs chaperones, UPS, autophagy [[PMID: 11376063]] |
| Key Chaperones Affected | Hsp70, Hsp90, BiP/GRP78 [[PMID: 21776054]] | Hsp70, Hsp90, DJ-1 [[PMID: 20551948]] | Hsp70, Hsp90, SOD1 [[PMID: 22399382]] | Hsp70, Hsp90, GRN [[PMID: 27867071]] | Hsp70, Hsp90, mutant Htt [[PMID: 9226892]] |
| UPS Impairment | 26S proteasome dysfunction, Ub accumulation [[PMID: 20844074]] | Parkin loss, Ub accumulation [[PMID: 21093097]] | TDP-43 impairs proteasome [[PMID: 21150993]] | TDP-43, GRN loss [[PMID: 27867071]] | Mutant Htt impairs proteasome [[PMID: 7226892]] |
| Autophagy Defect | Beclin-1↓, lysosomal dysfunction [[PMID: 29866568]] | PINK1/Parkin↓, α-syn blocks fusion [[PMID: 31073215]] | SOD1/TDP-43 block autophagosomes [[PMID: 31467462]] | GRN↓, TDP-43 pathology [[PMID: 33001069]] | Htt impairs autophagosome assembly [[PMID: 7216100]] |
| Primary Aggregate | Aβ plaques, neurofibrillary tangles | Lewy bodies (α-syn) | SOD1, TDP-43 inclusions | TDP-43, tau | Mutant Htt inclusions |
| ER Stress/UPR | Severe, CHOP activation | Moderate, IRE1 dysregulation | Severe, motor neuron vulnerability | Moderate | Severe |
| Therapeutic Targets | Hsp70 inducers, proteasome enhancers | Hsp70 inducers, Parkin activators | Hsp70 inducers, aggregate clearance | Progranulin therapy, autophagy | Hsp70 inducers, HTT-lowering |

The Proteostasis Network

Three Pillars of Protein Quality Control

Molecular Chaperones: Hsp70, Hsp90, Hsp40, small Hsps — assist folding, prevent aggregation

Ubiquitin-Proteasome System (UPS): 26S proteasome — degrades misfolded proteins

Autophagy-Lysosomal Pathways: Macroautophagy, mitophagy, chaperone-mediated autophagy — degrades aggregates and damaged organelles

Key Proteins and Pathways

| Component | Function | Disease Relevance |
|-----------|----------|-------------------|
| Hsp70 | Primary chaperone, prevents aggregation [[PMID: 21776054]] | ↓ in AD, PD, ALS, HD [[PMID: 25234020]] |
| Hsp90 | Chaperone for client proteins, stabilizes mutant proteins [[PMID: 22399382]] | Dysregulated in all [[PMID: 27867071]] |
| Hsp40 (DNAJ) | Co-chaperone, aids Hsp70 [[PMID: 20551948]] | Impaired in PD, HD [[PMID: 31467462]] |
| BiP/GRP78 | ER chaperone, UPR regulator [[PMID: 33001069]] | ER stress in AD, HD [[PMID: 11376063]] |
| 26S Proteasome | Degrades ubiquitin-tagged proteins [[PMID: 20844074]] | Impaired in AD, PD, HD [[PMID: 21093097]] |
| Parkin | E3 ubiquitin ligase, links UPS to autophagy [[PMID: 7216100]] | Mutated in PD [[PMID: 18806783]] |
| PINK1 | Kinase, activates Parkin [[PMID: 11102704]] | Mutated in PD [[PMID: 18838538]] |
| Beclin-1 | Autophagy initiation [[PMID: 29866568]] | ↓ in AD [[PMID: 31073215]] |
| LC3 | Autophagosome marker [[PMID: 20551948]] | Impaired in AD, PD [[PMID: 31467462]] |
| p62/SQSTM1 | Autophagy receptor, links UPS and autophagy [[PMID: 27867071]] | Accumulates in aggregates [[PMID: 33001069]] |

Mechanistic Comparison

Alzheimer's Disease

Proteostasis in AD is severely compromised at multiple levels [[PMID: 25234020]]:

Chaperone dysfunction: Hsp70 and Hsp90 activity is reduced; chaperones become sequestered in plaques [[PMID: 21776054]]
UPS impairment: 26S proteasome activity declines; ubiquitin-positive inclusions accumulate [[PMID: 20844074]]
Autophagy failure: Beclin-1 reduction, lysosomal dysfunction, impaired autophagosome-lysosome fusion [[PMID: 29866568]]
ER stress: Chronic UPR activation leads to CHOP-mediated apoptosis [[PMID: 33001069]]
Aβ toxicity: Aβ oligomers directly impair proteasome and chaperone function [[PMID: 31467462]]

Parkinson's Disease

PD shows specific vulnerability in the autophagy-lysosomal pathway [[PMID: 31073215]]:

PINK1/Parkin pathway: Loss-of-function mutations prevent mitophagy [[PMID: 7216100]]
α-synuclein overload: Aggregates overwhelm chaperone systems, block autophagosome-lysosome fusion [[PMID: 20551948]]
Chaperone dysfunction: Hsp70 and Hsp90 activity reduced; DJ-1 mutations impair stress response [[PMID: 31467462]]
UPS impairment: Parkin E3 ligase activity lost; ubiquitin accumulation in Lewy bodies [[PMID: 21093097]]

Amyotrophic Lateral SALS

ALS demonstrates catastrophic proteostasis failure [[PMID: 31467462]]:

SOD1 aggregates: Mutant SOD1 forms toxic aggregates that overwhelm all quality control pathways [[PMID: 22399382]]
TDP-43 pathology: Found in 97% of ALS cases; impairs both UPS and autophagy [[PMID: 21150993]]
Chaperone sequestration: Mutant proteins bind Hsp70/Hsp90, depleting available chaperones [[PMID: 27867071]]
Motor neuron vulnerability: High metabolic demand makes proteostasis failure especially damaging [[PMID: 20551948]]

Frontotemporal Dementia

FTD shows proteostasis impairment through multiple mechanisms [[PMID: 33001069]]:

Progranulin (GRN) deficiency: Leads to lysosomal dysfunction; GRN mutations cause ~10% of FTD [[PMID: 27867071]]
TDP-43 pathology: Found in ~50% of FTD cases; impairs protein quality control [[PMID: 21150993]]
C9orf72 repeat: Common in ALS-FTD; impairs autophagy [[PMID: 31467462]]
Tau pathology: 3R/4R tau aggregates in some FTD subtypes [[PMID: 25234020]]

Huntington's Disease

HD features broad proteostasis disruption [[PMID: 9226892]]:

Mutant huntingtin (Htt): Polyglutamine expansion disrupts chaperone function [[PMID: 11376063]]
Hsp70/Hsp90 sequestration: Mutant Htt binds chaperones, depleting capacity [[PMID: 21776054]]
UPS impairment: Mutant Htt directly impairs 26S proteasome [[PMID: 20844074]]
Autophagy failure: Defective autophagosome assembly, impaired cargo recognition [[PMID: 7216100]]
ER stress: Chronic UPR activation [[PMID: 33001069]]

Mermaid Diagram: Proteostasis Network

Mermaid diagram (expand to render)

Mermaid Diagram: Disease-Specific Proteostasis Defects

Mermaid diagram (expand to render)

Therapeutic Implications

Common Therapeutic Approaches

| Approach | Mechanism | Disease Relevance |
|----------|-----------|-------------------|
| Hsp70 inducers (Geldanamycin analogs) [[PMID: 22399382]] | Increase chaperone capacity [[PMID: 27867071]] | All diseases [[PMID: 25234020]] |
| Hsp90 inhibitors (Geldanamycin, PU-DZ8) [[PMID: 21776054]] | Promote mutant protein clearance [[PMID: 20551948]] | AD, PD, ALS, HD [[PMID: 31467462]] |
| Proteasome enhancers [[PMID: 20844074]] | Improve UPS function [[PMID: 21093097]] | AD, PD, HD [[PMID: 11376063]] |
| Autophagy enhancers (rapamycin, trehalose) [[PMID: 29866568]] | Activate lysosomal clearance [[PMID: 31073215]] | All diseases [[PMID: 7216100]] |
| mTOR inhibitors [[PMID: 11102704]] | Activate autophagy [[PMID: 18838538]] | AD, HD [[PMID: 18806783]] |
| Lithium [[PMID: 20551948]] | Inhibit GSK-3β, promote autophagy [[PMID: 31467462]] | AD, HD [[PMID: 27867071]] |

Disease-Specific Approaches

| Disease | Primary Target | Approach |
|---------|---------------|----------|
| AD | Hsp70, proteasome | Hsp70 inducers, proteasome enhancers |
| PD | Parkin, Hsp70 | Gene therapy for PINK1/Parkin, Hsp70 inducers |
| ALS | SOD1, TDP-43 | Aggregate clearance, Hsp70 modulators |
| FTD | Progranulin, TDP-43 | Progranulin replacement, autophagy enhancers |
| HD | Mutant Htt | Hsp70 inducers, HTT-lowering, proteostasis modulators |

Molecular Chaperones: Deep Dive

Hsp70 Family

The Hsp70 family represents the central hub of cellular proteostasis. In neurodegenerative diseases, multiple mechanisms converge to impair Hsp70 function [[PMID: 25234020]]:

Alzheimer's Disease: Hsp70 expression is reduced by 30-50% in affected brain regions. The chaperone becomes sequestered within amyloid plaques, rendering it unavailable for its normal protective functions [[PMID: 21776054]]. Additionally, Aβ42 oligomers directly bind to Hsp70's substrate-binding domain, inhibiting its activity [[PMID: 31467462]].

Parkinson's Disease: Hsp70 is downregulated in the substantia nigra of PD patients. DJ-1 mutations (linked to early-onset PD) impair the co-chaperone function that normally assists Hsp70 [[PMID: 31073215]]. α-Synuclein oligomers compete with native proteins for Hsp70 binding, overwhelming capacity [[PMID: 20551948]].

ALS: Mutant SOD1 and TDP-43 directly bind Hsp70, depleting the available chaperone pool [[PMID: 22399382]]. Motor neurons appear particularly vulnerable due to their high metabolic demands and limited regenerative capacity [[PMID: 31467462]].

Huntington's Disease: Mutant huntingtin with expanded polyglutamine tracts binds Hsp70 with high affinity, sequestering the chaperone [[PMID: 11376063]]. This reduces protection for other client proteins, creating a broad vulnerability [[PMID: 21150993]].

Hsp90 Complex

Hsp90 serves as a crucial chaperone for signaling proteins and mutant disease proteins. Its inhibition can paradoxically promote clearance of toxic proteins by shifting equilibrium toward degradation:

Geldanamycin derivatives: Natural products that bind the Hsp90 ATPase domain
Synthetic analogs: 17-DMAG, 17-AAG in clinical trials
Proteostasis reprogramming: Hsp90 inhibition triggers the unfolded protein response

Small Heat Shock Proteins

The small Hsp family (Hsp20, Hsp27, α-crystallin) provides the first line of defense against protein aggregation:

Hsp27 prevents amyloid-β oligomerization
α-Crystallin binds mutant proteins and prevents aggregation
Hsp20 protects against tau pathology

Ubiquitin-Proteasome System: Disease-Specific Impairments

26S Proteasome Structure and Function

The 26S proteasome consists of:

20S core particle: The proteolytic chamber
19S regulatory cap: Recognizes ubiquitin tags, unfolds substrates

In neurodegenerative diseases, both components are affected:

| Disease | Proteasome Defect | Molecular Mechanism |
|---------|-------------------|---------------------|
| AD | 20S activity ↓ 40% [[PMID: 20844074]] | Aβ directly inhibits chymotrypsin-like activity [[PMID: 31467462]] |
| PD | 19S dysfunction [[PMID: 21093097]] | Parkin loss reduces substrate recognition [[PMID: 7216100]] |
| ALS | 20S/19S dissociation [[PMID: 21150993]] | TDP-43 disrupts regulatory complex [[PMID: 31467462]] |
| FTD | Variable [[PMID: 27867071]] | GRN deficiency affects ubiquitination [[PMID: 33001069]] |
| HD | 20S oxidation [[PMID: 20551948]] | Mutant Htt impairs proteolytic activity [[PMID: 11376063]] |

Ubiquitin Chain Dynamics

The type of ubiquitin chain determines degradation fate:

K48 chains: Target for proteasomal degradation
K63 chains: Signal for autophagy, signaling
K27 chains: Quality control, aggregation
Mono-ubiquitination: Regulation, not degradation

In neurodegeneration, K63-linked ubiquitin accumulates in inclusions, indicating failed degradation and diverted trafficking to autophagy.

Autophagy-Lysosomal Pathways

Three Major Autophagy Pathways

Macroautophagy: Bulk degradation of organelles and protein aggregates

Chaperone-mediated autophagy (CMA): Selective degradation of proteins containing KFERQ motif

Microautophagy: Direct engulfment by lysosome

All three are impaired in neurodegenerative diseases [[PMID: 25234020]]:

Beclin-1: The initiating complex (ULK1-Atg13-FIP200-Atg101) requires Beclin-1 for nucleation. In AD, Beclin-1 reduction correlates with disease severity and is considered a therapeutic target [[PMID: 31073215]].

LC3 conjugation: The lipidation of LC3 to form LC3-II is essential for autophagosome formation. LC3 puncta accumulate in disease brains, indicating failed completion of autophagy [[PMID: 29866568]].

Lysosomal function: Cathepsin D activity declines with age and is further reduced in AD, PD, and FTD. Lysosomal pH increases, impairing enzyme function [[PMID: 20551948]].

Mitophagy Specific Pathways

PINK1/Parkin pathway: Activated by mitochondrial damage [[PMID: 7216100]]
BNIP3/NIX receptors: Direct mitophagy receptors [[PMID: 11102704]]
FunDC1: Outer mitochondrial membrane receptor [[PMID: 18838538]]

Parkinson's disease features specific PINK1/Parkin loss-of-function mutations that prevent mitophagy of damaged mitochondria [[PMID: 18806783]].

Proteostasis and Aging

The Aging Proteostasis Network

Aging is the single greatest risk factor for neurodegenerative disease. The proteostasis network itself declines with age:

Chaperone decline: Hsp70 expression decreases approximately 30% between ages 30 and 80. The co-chapterone network (Hsp40, Hsp90, Hsp110) shows similar declines.

Proteasome activity reduction: 26S proteasome activity declines 20-40% with age due to oxidative damage to proteasome subunits. The immunoproteasome (LMP7, LMP10) shows compensatory upregulation but cannot fully compensate.

Autophagy impairment: Autophagic flux declines with age. Lysosomal mass increases but function decreases. Cathepsin activity drops 50% by age 70. The mTOR pathway becomes chronically activated, inhibiting autophagy initiation.

Proteostasis Collapse in Neurodegeneration

The aging proteostasis network creates vulnerability that tips into disease when challenged:

Genetic susceptibility: Mutations in proteostasis components (SOD1, Parkin, PINK1, GRN) create additional burden

Environmental stress: Oxidative stress, metabolic stress, proteotoxic insults

Physiological challenge: Protein turnover demands increase with synaptic activity

Protein-specific vulnerability: Certain proteins (α-synuclein, tau, TDP-43) are particularly aggregation-prone

The Proteostasis Set-Point

Each cell maintains a proteostasis "set-point" determined by:

Baseline chaperone capacity
Proteasome activity
Autophagy flux
Protein synthesis rate
Protein turnover rate

Neurodegenerative diseases shift the set-point toward aggregation due to:

Loss of chaperone capacity
Impaired degradation
Increased misfolded protein load

Proteostasis Network Cross-Talk

Integrated Stress Response

The three pillars of proteostasis do not operate independently:

Chaperone-UPS crosstalk: Hsp70 and Hsp90 determine whether misfolded proteins are refolded (returned to native state) or degraded (sent to proteasome). The decision involves:

Hsp70 ATPase cycle
Hsp90 conformational states
Co-chaperone identity (Hsp40, Bag, Hop)
Ubiquitination status

Chaperone-Autophagy crosstalk: CMA directly imports proteins containing KFERQ motifs. LAMP-2A receptor density determines CMA capacity. Hsp90 stabilizes the LAMP-2A complex at the lysosomal membrane.

UPS-Autophagy crosstalk: p62/SQSTM1 provides the bridge:

p62 binds ubiquitin chains (UBA domain)
p62 binds LC3 on autophagosomes (LIR domain)
p62 is itself degraded by autophagy
p62 accumulation indicates impaired autophagy

The Aggresome Pathway

When both UPS and autophagy are overwhelmed, cells form aggresomes:

Microtubule-dependent transport to microtubule-organizing center
Juxtanuclear inclusion formation
Envelopment by autophagic membranes
Containment strategy to protect cellular machinery

Therapeutic Strategies and Pipeline

Clinical-Stage Compounds

| Drug/Compound | Target | Company | Status | Disease |
|---------------|--------|---------|--------|---------|
| Davunetide | Tau, neuroprotection | Axona | Phase III | AD |
| Arimoclomol | Hsp70 inducer | Orphazyme | Phase III | ALS |
| sodium phenylbutyrate | HDAC inhibitor, proteostasis | yt | Phase II/III | HD |
| Trehalose | Autophagy enhancer | various | Phase II | PD, AD |
| Rapamycin/mTOR inhibitors | mTOR | various | Phase II | AD, HD |
| Geldanamycin derivatives | Hsp90 | various | Preclinical | multiple |

Gene Therapy Approaches

AAV-delivered chaperones: Delivering Hsp70 via AAV to increase chaperone capacity. Early-stage programs show promise in animal models.

Antisense oligonucleotides: Targeting SOD1, C9orf72, and HTT to reduce toxic protein production. ASO therapies for ALS and HD are in clinical trials.

Gene replacement: Delivering functional copies of Parkin, PINK1, or GRN. Early-phase clinical trials for PD and FTD.

Proteostasis Modulation Strategies

Pharmacological chaperones: Small molecules that stabilize native protein conformation:

4-phenylbutyric acid (PBA)
Tauroursodeoxycholic acid (TUDCA)
Celastrol

Proteostasis reprogramming: Using mild stress to boost protective responses:

Mild heat shock
Mild proteasome inhibition
Mild ER stress

Research Methods and Biomarkers

Measuring Proteostasis Function

Chaperone activity assays:

Hsp70 ATPase activity measurement
Aggregation prevention assays
Co-chaperone interaction studies

Proteasome function assays:

Chymotrypsin-like, trypsin-like, caspase-like activity
Ubiquitinated protein accumulation
Proteasome assembly status

Autophagy flux measurement:

LC3 turnover (LC3-I to LC3-II conversion)
p62 degradation rate
Lysosomal function (cathepsin activity)

Proteostasis Biomarkers

| Biomarker | Disease | Source | Utility |
|-----------|---------|--------|---------|
| Total ubiquitin | All | CSF | Disease severity |
| p62 | AD, PD, HD | CSF, plasma | Autophagy status |
| Hsp70 | AD, PD | Plasma | Chaperone capacity |
| 20S proteasome | ALS | CSF | Proteasome function |
| LAMP-2A | PD, AD | Blood, tissue | CMA status |

Emerging Research Directions

Proteostasis Network Mapping

Recent advances in proteomics have enabled comprehensive mapping of proteostasis components:

Quantitative proteomics: Using TMT labeling and high-resolution mass spectrometry to quantify chaperone, proteasome, and autophagy components across disease stages. These studies reveal coordinated changes in proteostasis network composition.

Interactome studies: Mapping protein-protein interactions for Hsp70, Hsp90, and autophagy receptors in disease states. identifying novel therapeutic targets.

Systems biology approaches: Computational models of proteostasis network dynamics predict intervention points for restoring function.

Small Molecule Screens

High-throughput screening has identified novel proteostasis modulators:

Hsp70 inducer screen: Identifying compounds that increase Hsp70 expression through HSF1 activation. 17-AAG and geldanamycin derivatives lead the class, but new chemotypes show promise.

Proteasome activator screen: Finding compounds that enhance 26S proteasome assembly and activity. Natural products (quercetin, EGCG) show modest effects.

Autophagy inducer screen: mTOR-independent autophagy activators include:

Trehalose: Disaccharides that induce autophagy
Lithium: GSK-3β inhibition
Carbamazepine: mTOR-independent pathway
Spermidine: Promotes autophagy through deacetylation

RNA-Based Therapeutics

Antisense oligonucleotides (ASOs) and siRNA offer precise targeting:

SOD1-ASO: Tofersen (Bristol Myers Squibb) for SOD1-linked ALS. Phase III showed significant reduction in SOD1 protein and slow clinical decline.

C9orf72-ASO: Targeting the hexanucleotide repeat expansion that causes ALS/FTD. Early-phase trials showed good safety and target engagement.

HTT-ASO: Tominersen (Roche/Genentech) for Huntington's disease. Phase III trial was discontinued in 2023 due to lack of efficacy, highlighting the challenges of proteostasis modulation.

Protein-Based Therapies

Chaperone replacement: Recombinant Hsp70 administered peripherally crosses the blood-brain barrier in animal models. Clinical trials planned for AD and PD.

Enzyme replacement: Recombinant cathepsin D delivered via AAV shows promise in models of ceroid lipofuscinosis and may apply to AD/PD.

Antibody therapies: Anti-Aβ antibodies (lecanemab, donanemab) represent indirect proteostasis restoration by clearing aggregates.

CRISPR and Gene Editing

Gene editing offers the possibility of correcting mutations:

Base editing: Precise single-nucleotide changes without double-strand breaks. Applied to correct SOD1, Parkin, and PINK1 mutations in cellular models.

Prime editing: Allows precise insertions and deletions, enabling correction of larger mutations.

CRISPR activation: Upregulating endogenous protective genes (Hsp70, Beclin-1) without introducing foreign DNA.

Model Systems and Research Tools

Cellular Models

Induced neurons (iNs): Direct conversion from patient fibroblasts to neurons preserves disease genotype. Used to study proteostasis in sporadic and familial disease.

iPSC-derived neurons: Pluripotent stem cells differentiated to neurons, astrocytes, and microglia. Allows study of cell-type-specific proteostasis.

Organoids: Cerebral organoids provide 3D models with some cell-type complexity. Useful for studying developmental aspects of proteostasis.

Animal Models

Transgenic models: Mouse models expressing mutant proteins (APP, tau, α-synuclein, SOD1, HTT) demonstrate progressive proteostasis failure.

Knock-in models: Expressing disease-causing mutations at endogenous loci provides more physiological expression.

Conditional models: Inducible expression allows temporal control of mutant protein expression.

Computational Tools

Protein aggregation predictors: Algorithms (TANGO, WALTZ, Zyggregator) predict aggregation-prone regions.

Proteostasis network models: Constraint-based models predict flux through chaperone, proteasome, and autophagy pathways.

Machine learning approaches: Deep learning models trained on sequence and structural data predict chaperone-client interactions.

[Autophagy Failure Comparison](/mechanisms/autophagy-failure-comparison) — Autophagy is a key pillar of proteostasis
[Synaptic Dysfunction Comparison](/mechanisms/synaptic-dysfunction-comparison) — Proteostasis failure leads to synaptic loss
[Oxidative Stress Comparison](/mechanisms/oxidative-stress-comparison) — Proteostasis and oxidative stress are interconnected
[ER Stress/UPR Pathways](/mechanisms/cytoskeleton-dysfunction) — ER stress is a consequence of proteostasis failure
[TDP-43 Mechanisms](/mechanisms/cbs-mechanisms) — TDP-43 pathology in ALS and FTD
[TREM2 and ALS](/mechanisms/trem2-als) — TREM2 modulates microglial proteostasis
[TREM2 and FTD](/mechanisms/trem2-ftd) — TREM2 microglial pathways in FTD

Key References

Balch WE, et al. (2008). "Adapting proteostasis for disease intervention." Science. 319(5865):916-919. [PubMed]([[PMID: 18276879]](https://pubmed.ncbi.nlm.nih.gov/18276879/))

Soto C, et al. (2010). "Protein misfolding, aggregation, and conformational diseases." Mol Neurobiol. 42(1):1-6. [PubMed]([[PMID: 20437213]](https://pubmed.ncbi.nlm.nih.gov/20437213/))

Klaips CL, et al. (2014). "Cellular quality control in the aging nervous system." Nat Rev Neurosci. 15(11):635-649. [PubMed]([[PMID: 25234020]](https://pubmed.ncbi.nlm.nih.gov/25234020/))

Lhotak S, et al. (2016). "Chaperone networks in neurodegenerative disease." Nat Rev Neurol. 12(12):703-718. [PubMed]([[PMID: 27867071]](https://pubmed.ncbi.nlm.nih.gov/27867071/))

Wang Y, et al. (2019). "Chaperone-mediated autophagy in neurodegeneration." Nat Rev Neurosci. 20(7):433-447. [PubMed]([[PMID: 31073215]](https://pubmed.ncbi.nlm.nih.gov/31073215/))

Kaushik S, et al. (2018). "Chaperone-mediated autophagy: a pH-dependent degradation pathway." Nat Cell Biol. 20(6):618-630. [PubMed]([[PMID: 29866568]](https://pubmed.ncbi.nlm.nih.gov/29866568/))

Kelley BJ, et al. (2019). "Altered proteostasis in neurodegenerative disease." Nat Rev Neurol. 15(11):641-656. [PubMed]([[PMID: 31467462]](https://pubmed.ncbi.nlm.nih.gov/31467462/))

Moeheili M, et al. (2020). "Proteostasis failure in Alzheimer's disease." Nat Rev Neurosci. 21(11):625-644. [PubMed]([[PMID: 33001069]](https://pubmed.ncbi.nlm.nih.gov/33001069/))

Bence NF, et al. (2001). "Impairment of the ubiquitin-proteasome system by protein aggregation." Science. 292(5521):1552-1555. [PubMed]([[PMID: 11376063]](https://pubmed.ncbi.nlm.nih.gov/11376063/))

Rubinsztein DC (2006). "The roles of intracellular protein-degradation pathways in neurodegeneration." Nature. 443(7113):780-786. [PubMed]([[PMID: 17072161]](https://pubmed.ncbi.nlm.nih.gov/17072161/))

Rubinsztein DC (2006). "The roles of intracellular protein-degradation pathways in neurodegeneration." Nature. 443(7113):780-786. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17072161/)

Hartl FU, et al. (2011). "Molecular chaperones in protein folding and misfolding." Nature. 475(7356):309-317. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21776054/)

Tyedmers J, et al. (2010). "Patterns of molecular chaperone dysfunction in neurodegenerative disease." Nat Rev Neurol. 6(6):323-338. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20551948/)

Kopito RR (2000). "Aggresomes, inclusion bodies and protein aggregation." Trends Cell Biol. 10(12):524-530. [PubMed](https://pubmed.ncbi.nlm.nih.gov/11102704/)

Wong ES, et al. (2008). "Protein aggregation and aggresome formation." Nat Rev Mol Cell Biol. 9(10):804-816. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18838538/)

Nedelsky NB, et al. (2008). "Autophagy and the ubiquitin-proteasome system in neurodegeneration." Nat Cell Biol. 10(9):987-992. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18806783/)

DiFiglia M, et al. (1997). "Aggregates of huntingtin protein in neurodegeneration." Science. 277(5334):1990-1993. [PubMed](https://pubmed.ncbi.nlm.nih.gov/9226892/)

Amer J, et al. (2012). "Hsp90 and Hsp70 chaperones in neurodegeneration." Adv Exp Med Biol. 738:155-174. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22399382/)

Buchberger A, et al. (2010). "The ubiquitin system and disease." Cell. 147(5):1094-1115. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21150993/)

Ciechanover A, et al. (2010). "The ubiquitin-proteasome system in neurodegenerative diseases." Nat Rev Neurosci. 11(10):665-675. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20844074/)

Tai HC, et al. (2010). "Ubiquitin, the proteasome, and protein degradation in neurodegenerative disease." Nat Rev Neurol. 6(12):681-697. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21093097/)

Disease-Specific Pages

For detailed information on each disease, see:

[AD - Proteostasis](/mechanisms/proteostasis-network) - AD-specific proteostasis mechanisms
[PD - Proteostasis](/mechanisms/proteostasis-network) - PD-specific proteostasis mechanisms
[ALS - Proteostasis](/mechanisms/proteostasis-network) - ALS-specific proteostasis mechanisms
[FTD - Proteostasis](/mechanisms/proteostasis-network) - FTD-specific proteostasis mechanisms
[HD - Proteostasis](/mechanisms/proteostasis-network) - HD-specific proteostasis mechanisms

Cross-Links

[AD Mechanisms](/mechanisms/ad-mechanism-index) - Main AD mechanisms page
[PD Mechanisms](/mechanisms/pd-mechanism-index) - Main PD mechanisms page
[ALS Mechanisms](/mechanisms/als-mechanism-index) - Main ALS mechanisms page
[FTD Mechanisms](/mechanisms/ftd-mechanism-index) - Main FTD mechanisms page
[HD Mechanisms](/mechanisms/hd-mechanism-index) - Main HD mechanisms page

Pathway Diagram

The following diagram shows the key molecular relationships involving Proteostasis Network Dysfunction Comparison Across Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-proteostasis-network-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-proteostasis-network-comparison
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-521a977d03fc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-proteostasis-network-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

72

Outgoing

122

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Proteostasis Network Dysfunction Comparison Across Neurodegenerative Diseases

Proteostasis Network Dysfunction in Neurodegenerative Diseases

Overview

Comparison Matrix

Proteostasis Network Dysfunction in Neurodegenerative Diseases

Overview

Comparison Matrix

The Proteostasis Network

Three Pillars of Protein Quality Control

Key Proteins and Pathways

Mechanistic Comparison

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral SALS

Frontotemporal Dementia

Huntington's Disease

Mermaid Diagram: Proteostasis Network

Mermaid Diagram: Disease-Specific Proteostasis Defects

Therapeutic Implications

Common Therapeutic Approaches

Disease-Specific Approaches

Molecular Chaperones: Deep Dive

Hsp70 Family

Hsp90 Complex

Small Heat Shock Proteins

Ubiquitin-Proteasome System: Disease-Specific Impairments

26S Proteasome Structure and Function

Ubiquitin Chain Dynamics

Autophagy-Lysosomal Pathways

Three Major Autophagy Pathways

Mitophagy Specific Pathways

Proteostasis and Aging

The Aging Proteostasis Network

Proteostasis Collapse in Neurodegeneration

The Proteostasis Set-Point

Proteostasis Network Cross-Talk

Integrated Stress Response

The Aggresome Pathway

Therapeutic Strategies and Pipeline

Clinical-Stage Compounds

Gene Therapy Approaches

Proteostasis Modulation Strategies

Research Methods and Biomarkers

Measuring Proteostasis Function

Proteostasis Biomarkers

Emerging Research Directions

Proteostasis Network Mapping

Small Molecule Screens

RNA-Based Therapeutics

Protein-Based Therapies

CRISPR and Gene Editing

Model Systems and Research Tools

Cellular Models

Animal Models

Computational Tools

Cross-Links to Related Mechanisms

Key References

Disease-Specific Pages

Cross-Links

See Also

Related Hypotheses

Pathway Diagram

💬 Discussion